Skip to main content
Clinical Trials/ISRCTN99451262
ISRCTN99451262
Active, not recruiting
未知

Genetic screening in Parkinson’s disease patients to identify GBA1 mutation carriers for future clinical trials

Vanqua Bio Inc.0 sites1,000 target enrollmentNovember 8, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
Parkinson's disease, Parkinsonism
Sponsor
Vanqua Bio Inc.
Enrollment
1000
Status
Active, not recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 8, 2023
End Date
November 30, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Vanqua Bio Inc.

Eligibility Criteria

Inclusion Criteria

  • 1\. Age 40\-80
  • 2\. All participants must understand and provide written informed consent prior to any study\-specific procedures
  • 3\. Able to speak, read, and understand study procedures in Dutch sufficiently to allow completion of all study assessments
  • 4\. Confirmed clinical diagnosis of Parkinson’s disease by a neurologist within the last 5 years, based on presence of bradykinesia and either resting tremor and/or muscular rigidity in at least one limb
  • 5\. Willing to be contacted regarding potential participation in future interventional clinical trials

Exclusion Criteria

  • 1\. History of a significant medical or psychiatric comorbidity that would preclude the subject’s participation in an interventional clinical trial
  • 2\. Known GBA\-1 mutation for Parkinson’s disease

Outcomes

Primary Outcomes

Not specified

Similar Trials